GlassScriptPhysician profile
Muhammad K Shakeel
NPI 1477558740
$3,989.24
in general payments reported to CMS, 2019-2025
35 companies · $601 in 2025
The $601 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $557 · 2021: $467 · 2022: $606 · 2023: $717 · 2024: $492 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.63 |
| Education | $108.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $446.63 | 2019-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $341.07 | 2019-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $326.45 | 2020-2025 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $322.81 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $274.30 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $258.37 | 2019-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $241.63 | 2019-2023 | Jesduvroq, Benlysta |
| Akebia Therapeutics INC | $233.17 | 2020-2023 | Auryxia |
| Novartis Pharmaceuticals Corporation | $210.13 | 2020-2025 | |
| Fresenius USA Marketing, INC. | $194.42 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $142.04 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $109.93 | 2022-2024 | Lupkynis |
| Travere Therapeutics, INC. | $82.16 | 2022-2025 | |
| Lilly USA, LLC | $76.05 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $75.34 | 2019-2023 | Injectafer |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $66.42 | 2019-2023 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.79 | 2021-2025 | Jardiance |
| Horizon Therapeutics Plc | $64.18 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $62.77 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $58.56 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $55.92 | 2022 | |
| Ascendis Pharma Endocrinology INC | $55.37 | 2025 | Yorvipath |
| Ani Pharmaceuticals, INC. | $29.89 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.64 | 2023 | Ultomiris |
| Ardelyx, INC. | $20.81 | 2023 | Ibsrela |
| Scpharmaceuticals INC. | $19.70 | 2025 | |
| Alnylam Pharmaceuticals INC. | $19.02 | 2023 | Givlaari |
| Hikma Pharmaceuticals USA | $18.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.12 | 2019 | |
| Melinta Therapeutics, LLC | $17.82 | 2019 | |
| Nxstage Medical, INC. | $16.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.80 | 2022 | |
| Merck Sharp & Dohme LLC | $15.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Shakeel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.